Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results

Noah Lechtzin, Nicole Mayer-Hamblett, Natalie E. West, Sarah Allgood, Ellen Wilhelm, Umer Khan, Moira L. Aitken, Bonnie W. Ramsey, Michael P. Boyle, Peter J. Mogayzel, Ronald L. Gibson, David Orenstein, Carlos Milla, John P. Clancy, Veena Antony, Christopher H. Goss

Research output: Contribution to journalArticle

Abstract

Rationale: Individuals with cystic fibrosis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung function and reduced quality of life. Objectives: The goal of this study was to determine if an intervention directed toward early detection of pulmonary exacerbations using home spirometry and symptom monitoring would result in slower decline in lung function than in control subjects. Methods: We conducted a multicenter, randomized trial at 14 CF centers with subjects at least 14 years old. The early intervention arm subjects measured home spirometry and symptoms electronically twice per week. Sites were notified if a participant met criteria for an exacerbationandcontactedparticipantstodetermineiftreatmentfor acute exacerbation was required. Participants in the usual care arm were seen every 3 months and were asked to contact the site if they were concerned about worsening pulmonary symptoms. Measurements and Main Results: The primary outcome was the 52-week change in FEV1. Secondary outcomes included time to first exacerbationandsubsequentexacerbation,qualityoflife,andchangein weight. A total of 267 patients were randomized, and the study arms were well matched at baseline. There was no significant difference betweenstudyarmsin52-weekmeanchangeinFEV1slope(meanslope difference, 0.00 L, 95% confidence interval, 20.07 to 0.07; P = 0.99). The early intervention arm subjects detected exacerbations more frequently than usual care arm subjects (time to first exacerbation hazard ratio, 1.45; 95% confidence interval, 1.09 to 1.93; P = 0.01). Adverseeventswerenotsignificantlydifferentbetweentreatmentarms. Conclusions: An intervention of home monitoring among patients with CF was able to detect more exacerbations than usual care, but this did not result in slower decline in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT01104402).

Original languageEnglish (US)
Pages (from-to)1144-1151
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume196
Issue number9
DOIs
StatePublished - Nov 1 2017

Fingerprint

Physiologic Monitoring
Cystic Fibrosis
Lung
Spirometry
Confidence Intervals
Multicenter Studies
Quality of Life
Clinical Trials
Weights and Measures

Keywords

  • Clinical trial
  • Cystic fibrosis
  • Home monitoring
  • Pulmonary exacerbation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results. / Lechtzin, Noah; Mayer-Hamblett, Nicole; West, Natalie E.; Allgood, Sarah; Wilhelm, Ellen; Khan, Umer; Aitken, Moira L.; Ramsey, Bonnie W.; Boyle, Michael P.; Mogayzel, Peter J.; Gibson, Ronald L.; Orenstein, David; Milla, Carlos; Clancy, John P.; Antony, Veena; Goss, Christopher H.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 196, No. 9, 01.11.2017, p. 1144-1151.

Research output: Contribution to journalArticle

Lechtzin, N, Mayer-Hamblett, N, West, NE, Allgood, S, Wilhelm, E, Khan, U, Aitken, ML, Ramsey, BW, Boyle, MP, Mogayzel, PJ, Gibson, RL, Orenstein, D, Milla, C, Clancy, JP, Antony, V & Goss, CH 2017, 'Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results', American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 9, pp. 1144-1151. https://doi.org/10.1164/rccm.201610-2172OC
Lechtzin, Noah ; Mayer-Hamblett, Nicole ; West, Natalie E. ; Allgood, Sarah ; Wilhelm, Ellen ; Khan, Umer ; Aitken, Moira L. ; Ramsey, Bonnie W. ; Boyle, Michael P. ; Mogayzel, Peter J. ; Gibson, Ronald L. ; Orenstein, David ; Milla, Carlos ; Clancy, John P. ; Antony, Veena ; Goss, Christopher H. / Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results. In: American Journal of Respiratory and Critical Care Medicine. 2017 ; Vol. 196, No. 9. pp. 1144-1151.
@article{74cf6786348e4824a88147dd896530bc,
title = "Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results",
abstract = "Rationale: Individuals with cystic fibrosis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung function and reduced quality of life. Objectives: The goal of this study was to determine if an intervention directed toward early detection of pulmonary exacerbations using home spirometry and symptom monitoring would result in slower decline in lung function than in control subjects. Methods: We conducted a multicenter, randomized trial at 14 CF centers with subjects at least 14 years old. The early intervention arm subjects measured home spirometry and symptoms electronically twice per week. Sites were notified if a participant met criteria for an exacerbationandcontactedparticipantstodetermineiftreatmentfor acute exacerbation was required. Participants in the usual care arm were seen every 3 months and were asked to contact the site if they were concerned about worsening pulmonary symptoms. Measurements and Main Results: The primary outcome was the 52-week change in FEV1. Secondary outcomes included time to first exacerbationandsubsequentexacerbation,qualityoflife,andchangein weight. A total of 267 patients were randomized, and the study arms were well matched at baseline. There was no significant difference betweenstudyarmsin52-weekmeanchangeinFEV1slope(meanslope difference, 0.00 L, 95{\%} confidence interval, 20.07 to 0.07; P = 0.99). The early intervention arm subjects detected exacerbations more frequently than usual care arm subjects (time to first exacerbation hazard ratio, 1.45; 95{\%} confidence interval, 1.09 to 1.93; P = 0.01). Adverseeventswerenotsignificantlydifferentbetweentreatmentarms. Conclusions: An intervention of home monitoring among patients with CF was able to detect more exacerbations than usual care, but this did not result in slower decline in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT01104402).",
keywords = "Clinical trial, Cystic fibrosis, Home monitoring, Pulmonary exacerbation",
author = "Noah Lechtzin and Nicole Mayer-Hamblett and West, {Natalie E.} and Sarah Allgood and Ellen Wilhelm and Umer Khan and Aitken, {Moira L.} and Ramsey, {Bonnie W.} and Boyle, {Michael P.} and Mogayzel, {Peter J.} and Gibson, {Ronald L.} and David Orenstein and Carlos Milla and Clancy, {John P.} and Veena Antony and Goss, {Christopher H.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1164/rccm.201610-2172OC",
language = "English (US)",
volume = "196",
pages = "1144--1151",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results

AU - Lechtzin, Noah

AU - Mayer-Hamblett, Nicole

AU - West, Natalie E.

AU - Allgood, Sarah

AU - Wilhelm, Ellen

AU - Khan, Umer

AU - Aitken, Moira L.

AU - Ramsey, Bonnie W.

AU - Boyle, Michael P.

AU - Mogayzel, Peter J.

AU - Gibson, Ronald L.

AU - Orenstein, David

AU - Milla, Carlos

AU - Clancy, John P.

AU - Antony, Veena

AU - Goss, Christopher H.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Rationale: Individuals with cystic fibrosis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung function and reduced quality of life. Objectives: The goal of this study was to determine if an intervention directed toward early detection of pulmonary exacerbations using home spirometry and symptom monitoring would result in slower decline in lung function than in control subjects. Methods: We conducted a multicenter, randomized trial at 14 CF centers with subjects at least 14 years old. The early intervention arm subjects measured home spirometry and symptoms electronically twice per week. Sites were notified if a participant met criteria for an exacerbationandcontactedparticipantstodetermineiftreatmentfor acute exacerbation was required. Participants in the usual care arm were seen every 3 months and were asked to contact the site if they were concerned about worsening pulmonary symptoms. Measurements and Main Results: The primary outcome was the 52-week change in FEV1. Secondary outcomes included time to first exacerbationandsubsequentexacerbation,qualityoflife,andchangein weight. A total of 267 patients were randomized, and the study arms were well matched at baseline. There was no significant difference betweenstudyarmsin52-weekmeanchangeinFEV1slope(meanslope difference, 0.00 L, 95% confidence interval, 20.07 to 0.07; P = 0.99). The early intervention arm subjects detected exacerbations more frequently than usual care arm subjects (time to first exacerbation hazard ratio, 1.45; 95% confidence interval, 1.09 to 1.93; P = 0.01). Adverseeventswerenotsignificantlydifferentbetweentreatmentarms. Conclusions: An intervention of home monitoring among patients with CF was able to detect more exacerbations than usual care, but this did not result in slower decline in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT01104402).

AB - Rationale: Individuals with cystic fibrosis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung function and reduced quality of life. Objectives: The goal of this study was to determine if an intervention directed toward early detection of pulmonary exacerbations using home spirometry and symptom monitoring would result in slower decline in lung function than in control subjects. Methods: We conducted a multicenter, randomized trial at 14 CF centers with subjects at least 14 years old. The early intervention arm subjects measured home spirometry and symptoms electronically twice per week. Sites were notified if a participant met criteria for an exacerbationandcontactedparticipantstodetermineiftreatmentfor acute exacerbation was required. Participants in the usual care arm were seen every 3 months and were asked to contact the site if they were concerned about worsening pulmonary symptoms. Measurements and Main Results: The primary outcome was the 52-week change in FEV1. Secondary outcomes included time to first exacerbationandsubsequentexacerbation,qualityoflife,andchangein weight. A total of 267 patients were randomized, and the study arms were well matched at baseline. There was no significant difference betweenstudyarmsin52-weekmeanchangeinFEV1slope(meanslope difference, 0.00 L, 95% confidence interval, 20.07 to 0.07; P = 0.99). The early intervention arm subjects detected exacerbations more frequently than usual care arm subjects (time to first exacerbation hazard ratio, 1.45; 95% confidence interval, 1.09 to 1.93; P = 0.01). Adverseeventswerenotsignificantlydifferentbetweentreatmentarms. Conclusions: An intervention of home monitoring among patients with CF was able to detect more exacerbations than usual care, but this did not result in slower decline in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT01104402).

KW - Clinical trial

KW - Cystic fibrosis

KW - Home monitoring

KW - Pulmonary exacerbation

UR - http://www.scopus.com/inward/record.url?scp=85032708784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032708784&partnerID=8YFLogxK

U2 - 10.1164/rccm.201610-2172OC

DO - 10.1164/rccm.201610-2172OC

M3 - Article

C2 - 28608719

AN - SCOPUS:85032708784

VL - 196

SP - 1144

EP - 1151

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -